Comparative Study of Cancer Treatment Potential Effects of Tumor-Treating Fields and Cold Atmospheric Plasma

Q3 Physics and Astronomy

Plasma Medicine Pub Date : 2020-01-01 DOI:10.1615/plasmamed.2020033045

X. Yao, Isaac Goldstein, Li Lin, J. Sherman, M. Keidar

引用次数: 4

Abstract

Tumor-treating fields (TTFields) therapy is well known and approved by the Food and Drug Administration for treatment of adult patients who suffer with glioblastoma. The method uses low-intensity and intermediate-frequency alternating electric fields to produce an inhibitory effect on cancerous cells. However, it involves 24 h of treatment time to produce anticancer effects. A new modality of cancer treatment called cold plasma therapy (CPT) has been shown both in vitro and in mice models to significantly treat dozens of cancer types. CPT is based on the therapeutic effect of cold atmospheric plasma (CAP), a type of ionized gas that operates at close to room temperature and provides electromagnetic radiation as well as reactive oxygen and nitrogen species, both cytotoxic to cancer cells. With this study, after investigating the anticancer effects of TTFields and CAP on glioblastoma cells, we have found that CAP has superior ability

查看原文本刊更多论文

肿瘤治疗场与低温大气等离子体治疗肿瘤潜在效果的比较研究

肿瘤治疗领域(TTFields)疗法是众所周知的，并被食品和药物管理局批准用于治疗成年胶质母细胞瘤患者。该方法利用低强度和中频交变电场对癌细胞产生抑制作用。然而，它需要24小时的治疗时间才能产生抗癌效果。一种新的癌症治疗方式被称为冷血浆疗法(CPT)，已经在体外和小鼠模型中显示出对数十种癌症类型的显着治疗。CPT是基于冷大气等离子体(CAP)的治疗效果，CAP是一种电离气体，在接近室温的条件下工作，提供电磁辐射以及活性氧和活性氮，这两种物质都对癌细胞具有细胞毒性。本研究在考察了TTFields和CAP对胶质母细胞瘤细胞的抗癌作用后，发现CAP具有更强的抗癌能力

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Plasma Medicine Physics and Astronomy-Physics and Astronomy (all)

CiteScore

1.40

自引率

0.00%

发文量

期刊介绍： Technology has always played an important role in medicine and there are many journals today devoted to medical applications of ionizing radiation, lasers, ultrasound, magnetic resonance and others. Plasma technology is a relative newcomer to the field of medicine. Experimental work conducted at several major universities, research centers and companies around the world over the recent decade demonstrates that plasma can be used in variety of medical applications. It is already widely used surgeries and endoscopic procedures. It has been shown to control properties of cellular and tissue matrices, including biocompatibility of various substrates. Non-thermal plasma has been demonstrated to deactivate dangerous pathogens and to stop bleeding without damaging healthy tissue. It can be used to promote wound healing and to treat cancer. Understanding of various mechanisms by which plasma can interact with living systems, including effects of reactive oxygen species, reactive nitrogen species and charges, has begun to emerge recently. The aim of the Plasma Medicine journal will be to provide a forum where the above topics as well as topics closely related to them can be presented and discussed. Existing journals on plasma science and technology are aimed for audiences with primarily engineering and science background. The field of Plasma Medicine, on the other hand, is highly interdisciplinary. Some of prospective readers and contributors of the Plasma Medicine journal are expected to have background in medicine and biology. Others might be more familiar with plasma science. The goal of the proposed Plasma Medicine journal is to bridge the gap between audiences with such different backgrounds, without sacrificing the quality of the papers be their emphasis on medicine, biology or plasma science and technology.